A single injection of Alnylam’s RNA interference candidate ALN-APP – which is designed to switch off the production of amyloid precursor protein (APP) in the central nervous system – was ...

"This new app will help people living with ATTR amyloidosis track their disease progression, while offering healthcare teams a more accurate picture of their patients’ disease," he said. Alnylam ...

Alnylam and Regeneron are also jointly developing another candidate, mivelsiran (formerly ALN-APP), for treating early-onset ...

Beyond ATTR-CM, Alnylam is advancing several other promising pipeline candidates. Zilebesiran and ALN-APP are highlighted as key programs with significant potential. The company is also exploring ...